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Background: Elderly patients with metastatic melanoma have different disease characteristics and a poorer
prognosis than younger patients. Data from clinical trials and expanded access programmes (EAPs) suggest
ipilimumab confers a consistent survival benefit and has a similar safety profile across different age groups of
patients with metastatic melanoma. Here we report the efficacy and safety of ipilimumab 3 mg/kg in elderly
patients enrolled in an EAP in Italy.
Methods: Patients aged > 70 years with pretreated melanoma received ipilimumab 3 mg/kg every 3 weeks for four
doses through an EAP. Tumour response was evaluated at baseline and after completion of induction therapy using
immune-related response criteria and patients were monitored throughout the treatment period for adverse events
(AEs), including immune-related AEs.
Results: The immune-related disease control rate among 188 evaluable patients was 38%, including four patients with
an immune-related complete response, 24 with an immune-related partial response and 44 with immune-related stable
disease. Median progression-free survival (PFS) was 4.0 months and the 1- and 2-year PFS rates were 21% and 12%,
respectively. Median overall survival (OS) was 8.9 months; 1- and 2-year OS rates were 38% and 22%, respectively. The
safety profile of ipilimumab was consistent with that observed in the general population of the Italian EAP and
treatment-related AEs generally resolved within a median of 2 weeks with treatment as per protocol-specific guidelines.
Conclusions: These results suggest ipilimumab is a feasible treatment option in elderly patients with metastatic
melanoma. Ipilimumab treatment was generally well tolerated and resulted in clinical benefit and extended survival in
elderly patients treated at centres in Italy.
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Historically, patients with unresectable Stage III or Stage
IV (advanced) melanoma had limited treatment options
and poor survival outcomes, with older patients having a
particularly dismal prognosis [1,2]. In 2010, there were
an estimated 13.6 melanoma-related deaths per 100 000* Correspondence: mgaliz@tiscali.it
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article, unless otherwise stated.US inhabitants aged > 65 years compared with 1.2 per
100 000 US inhabitants aged ≤ 65 years [3]. Current epi-
demiological data suggest the incidence of melanoma
continues to rise in the elderly population despite indi-
cations that it has plateaued in younger people [3,4].
Combined with a rapid increase in the proportion of eld-
erly people, this has resulted in melanoma becoming an
increasingly important health concern in the developed
world [5].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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erly patients with melanoma have been proposed. Older
melanoma patients may be more predisposed to distant
metastasis arising from the haematological distribution of
tumour cells than younger patients due to changes in
lymphatic drainage with ageing [6]. In addition, elderly pa-
tients present with thicker melanomas, a higher mitotic
rate and increased incidence of ulceration [7], all of which
are associated with a worse prognosis [1]. It is likely, how-
ever, that the high mortality rates among elderly patients
result from a number of age-related variables preventing
optimal management of this disease [8].
One confounding factor that may contribute to the
poor prognosis of elderly patients with metastatic mel-
anoma is a weakening of the immune system with age, a
process referred to as immunosenescence. Therefore,
the possibility of using immune-based therapies to pro-
mote immune function is an attractive therapeutic op-
tion [8,9]. In 2011, the novel immunotherapy agent
ipilimumab was the first agent approved for the treat-
ment of patients with advanced melanoma in over three
decades [10]. Ipilimumab is a fully human monoclonal
antibody directed against cytotoxic T-lymphocyte-
associated antigen-4 (CTLA-4), a negative regulator of
T-cell-mediated immune responses. By blocking CTLA-
4, ipilimumab enables prolonged T-cell activation, prolif-
eration and tumour infiltration, thereby potentiating en-
dogenous antitumour responses [11].
Ipilimumab 3 mg/kg is now approved in over 40 coun-
tries for the treatment of adult patients with advanced
melanoma. In Phase III trials, ipilimumab treatment sig-
nificantly extended overall survival (OS) compared with
control in both pretreated and treatment-naϊve patients
[12,13], and follow-up data from clinical trials suggest
ipilimumab can provide durable clinical benefit and
long-term survival [13-15]. Furthermore, retrospective
analyses of clinical trial data suggest the survival benefit
conferred by ipilimumab is independent of age, per-
formance status and stage of metastasis, despite the
identification of these variables as significant prognostic
indicators [1,16,17].
Expanded access programmes (EAPs) provide an op-
portunity to assess the efficacy and safety of ipilimumab
at its approved dose of 3 mg/kg in elderly patients out-
side of a clinical trial, in a setting more representative of
daily practice. Efficacy and safety results from the Spanish
and US EAPs suggest ipilimumab 3 mg/kg is a feasible
treatment option in elderly patients with metastatic
melanoma [18-20]. Here, we describe the efficacy and
safety of ipilimumab 3 mg/kg in elderly (> 70 years old)
patients with metastatic melanoma treated at Italian cen-
tres participating in the European EAP. Data from other
patient subgroups treated in the Italian EAP have been
published previously [21,22].Methods
Patients
Patients were eligible to be included in the EAP if they
had life-threatening unresectable Stage III or Stage IV
melanoma and had failed to respond or were intolerant
to at least one prior systemic treatment. Ipilimumab was
available on physicians’ request where no alternative
treatment option was available. An Eastern Cooperative
Oncology Group (ECOG) performance status of 0, 1 or
2 was required, and an interval of at least 28 days since
completion of treatment with chemotherapy, biochem-
otherapy, surgery, radiation, or immunotherapy recom-
mended. The protocol for the EAP was approved by a
local independent ethics committee and all participating
patients provided signed informed consent before enrol-
ment. The study was approved by the ECs of all partici-
pating centers.
Treatment and clinical assessment
Ipilimumab 3 mg/kg was administered intravenously
over 90 minutes, every 3 weeks for four doses. Disease
evaluation was performed at baseline and after comple-
tion of induction therapy using immune-related re-
sponse criteria (irRC) [23]. Clinical response was defined
as immune-related complete response (irCR), partial re-
sponse (irPR), stable disease (irSD) or progressive dis-
ease. Immune-related disease control (irDC) was defined
as an irCR, irPR or irSD lasting ≥ 3 months. All patients
were monitored for safety throughout the EAP, and ad-
verse events (AEs), including immune-related AEs
(irAEs), graded according to the Common Terminology
Criteria for Adverse Events, version 3.0.
Statistical analysis
Patient and disease characteristics were analysed using
descriptive statistics with data expressed as relative fre-
quencies (percentages) for discrete variables, or median
and range for continuous variables. Progression-free sur-
vival (PFS) and OS were estimated using Kaplan–Meier
analysis and expressed as median values with corre-
sponding two-sided 95% confidence intervals (CIs).
Results
Patients
A total of 855 patients participated in the EAP from
June 2010 to January 2012 across 55 Italian centres, in-
cluding 193 patients (23%) aged > 70 years (median age,
75; range 71–88 years) of which 27 were aged ≥ 80 years.
Baseline patient and disease characteristics are shown in
Table 1. Of the 193 elderly patients, 132 patients (68%)
received all four doses, 24 (12%) received three doses, 17
(9%) received two doses and 20 patients (10%) received
one dose of ipilimumab 3 mg/kg. Reasons for not com-
pleting all four doses of ipilimumab therapy comprised
Table 1 Baseline patient characteristics
Characteristic (N = 855) Patients aged
> 70 years
Patients aged
≤ 70 years
Total number of patients 193 662
Median age, years (range) 75 (71–88) 55 (16–70)
Male/female, n (%) 112 (58)/81 (42) 348 (53)/314 (47)
ECOG performance status, n (%)
0 105 (54) 458 (69)
1 83 (43) 184 (28)
2 5 (3) 20 (3)
Time from diagnosis, months (range) 35 (3–280) 40 (3–280)
LDH level, n/n (%)a
< 1.10 ULN 108/175 (62) 336/545 (62)
≥ 1.10 ULN 67/175 (38) 209/545 (38)
Number of previous therapies, n (%)
1 128 (66) 369 (56)
2 41 (21) 192 (29)
≥ 3 24 (13) 101 (15)
Previous therapy, n (%)
Dacarbazine 113 (59) 377 (57)
Fotemustine 54 (28) 268 (41)
Platinum-based chemotherapy 42 (22) 274 (41)
Temozolomide 40 (21) 149 (23)
Interferon 22 (11) 172 (26)
BRAF inhibitor 8 (4) 51 (8)
Patients with brain metastases, n (%) 17 (9) 129 (20)
Patients with liver metastases, n (%) 75 (39) 264 (40)
aLDH data unavailable for 135 patients.
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; ULN,
upper limit of normal.
Table 2 Tumour response
Patients, n (%)
Response
according
to irRC
Aged > 70
years
(n = 188)
Aged ≥ 80
years
(n = 26)
Aged ≤ 70
years
(n = 645)
irCR 4 (2) 0 (0) 25 (4)
irPR 24 (13) 1 (4) 58 (9)
irSD 44 (23) 7 (27) 131 (20)
irPD 116 (62) 18 (69) 431 (67)
irBORR 28 (15) 1 (4) 83 (13)
irDCR 72 (38) 8 (31) 214 (33)
[Note to authors: summarised these data as a table and added data for
patients ≥80 years].
irBORR, immune-related best overall response rate; irCR, immune-related
complete response; irDCR, immune-related disease control rate; irPD, immune-
related progressive disease; irPR, immune-related partial response; irRC,
immune-related response criteria; irSD, immune-related stable disease.
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without progression (n = 3), AEs unrelated to treatment
(n = 4), dose skipping (n = 2), patient refusal (n =1), loss
to follow up (n = 1), and unknown reasons (n = 3). Only
7 patients (4%) discontinued for reasons of treatment-
related toxicity.
Efficacy
Tumour assessment
With a median follow-up of 7.9 months (mean 9.7 months;
range 1–31 months), the irDC rate (irDCR) among 188
evaluable patients aged > 70 years was 38% (Table 2). This
included four patients (2%) with an irCR, 24 (13%) with an
irPR and 44 (23%) with irSD at any time according to
irRC, for an immune-related best overall response rate
(irBORR) of 15%. Five elderly patients were not evaluable
for response due to toxicity (n = 1), loss to follow up (n = 1),
only receiving one dose of ipilimumab (n = 1) or unknown
reasons (n = 2). The median duration of irDC in elderly pa-
tients was 11.5 months (95% CI 9.3–13.7). The irDCRamong 26 evaluable patients aged ≥ 80 years was 31%, com-
prising one patient (4%) with an irPR and seven patients
(27%) with irSD. With a median follow-up of 6.7 months
(range 1–34), the irDCR among 645 evaluable patients
aged ≤ 70 years was 33%. Of these, 25 patients (4%) had an
irCR, 58 (9%) an irPR and 131 (20%) had irSD at any time
according to irRC. The irBORR in patients aged ≤ 70 years
was therefore 13%.
Survival
As of April 2013, median PFS in patients > 70 years old
was 4.0 months (95% CI 3.0–5.0; Figure 1A); 1- and 2-
year PFS rates were 21% and 12%, respectively. By com-
parison, median PFS in younger patients (≤ 70 years)
was 3.7 months (95% CI 3.4–4.0), with 1- and 2-year
PFS rates of 20% and 11%, respectively. In the elderly pa-
tient group (> 70 years old), median OS was 8.9 months
(95% CI 7.2–10.6; Figure 1B); 1- and 2-year OS rates
were 38% and 22%, respectively. For patients aged ≤
70 years, median OS was 7.0 months (95% CI 6.1–7.9);
1- and 2-year OS rates in the younger age group were
35% and 19%, respectively. Differences between age
groups in median PFS and median OS were not statisti-
cally significant (P = 0.33 and P = 0.17, respectively).
Safety
The safety profile of ipilimumab in elderly patients was
comparable to that in the wider EAP population [24]. Of
the 193 patients aged > 70 years treated with ipilimumab,
96 (50%) reported an AE of any grade and among these
96 patients, 69 (36%) had AEs that were considered to
be treatment-related. Respective numbers for the 662
patients aged ≤ 70 years were 303 (46%) and 217 (33%).
The most frequently reported treatment-related AEs
among patients aged > 70 years were pruritus, rash, diar-
rhoea, nausea and liver toxicity (experienced by at least
2% of patients; Table 3). Median time to onset of
Figure 1 Kaplan-Meier estimates of progression free survival and overall survival by patient ages. A. Progression-free survival. B. OS,
overall survival; PFS, progression-free survival.
Table 3 Treatment-related AEs experienced by at least
2% of patients aged > 70 or ≤ 70 years
Patients aged
> 70 years
(n = 193), n (%)
Patients aged
≤ 70 years
(n = 662), n (%)
Treatment-related AEs experienced
by at least 2% of patients
Any
grade
Grade
III–IV
Any
grade
Grade
III–IV
Pruritus 11 (6) 0 47 (7) 1 (<1)
Rash 19 (10) 1 (<1) 45 (7) 3 (<1)
Diarrhoea 9 (5) 2 (1) 51 (8) 17 (3)
Nausea 5 (3) 0 42 (6) 2 (<1)
Liver toxicity 3 (2) 2 (1) 16 (2) 13 (2)
AEs, adverse events.
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0.1–12 weeks). Grade III–IV AEs were reported by 19
patients (10%) and considered ipilimumab-related in 11
patients (6%). Median time to onset of treatment-related
Grade III–IV AEs was 6 weeks (range 3–10 weeks). AEs
were generally reversible with treatment as per protocol-
specific guidelines. Median time to resolution of treatment-
related AEs of any grade was 2.0 weeks (range 0.1–4),
compared with a median of 1.7 weeks (0.1–11.1) among all
patients treated in the EAP in Italy [24].
Discussion
Elderly patients with metastatic melanoma have higher
rates of overall and disease-specific mortality than youn-
ger patients [7]. Furthermore, older patients are more
likely to have existing comorbidities, which often result
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therapies [25]. The EAP in Italy provided the opportun-
ity to assess the efficacy and safety of ipilimumab 3 mg/
kg in elderly patients with advanced melanoma outside
of a clinical trial setting.
Most other subgroup analyses have used a cut-off age
of 65 years when reporting the use of ipilimumab in eld-
erly patients [12,19,20,26]. Our results suggest ipilimu-
mab treatment is equally effective and safe in patients
with advanced melanoma who are aged over or under
70 years. This higher cut-off age may be more relevant
to the challenges associated with cancer treatment in an
aging society. Indeed, the cut-off for many clinical can-
cer studies is now 70 years and this is expected to be re-
vised upwards so that 75 years may soon be the standard
upper age limit for inclusion in a clinical trial [27,28].
Among the 855 patients who participated in the EAP in
Italy, almost one quarter were aged > 70 years and were
eligible for treatment. This figure is consistent with the
proportion of patients > 70 years diagnosed with melan-
oma in Italy as recorded in the Italian cancer registry,
demonstrating that the elderly patients treated as part of
the EAP can be considered as representative of the gen-
eral population of patients > 70 years with melanoma.
Elderly patients had long-lasting clinical responses and
prolonged survival with ipilimumab 3 mg/kg. The irBORR
and irDCR in patients aged > 70 years were similar to those
observed in the wider population of the Italian EAP [24]
and in 30 elderly patients (≥ 70 years old) treated at Span-
ish centres through the EAP [20]. One- and 2-year survival
rates of 38% and 22% are also comparable with those re-
ported for the total population and consistent with results
from the US EAP, in which 1-year survival rates for pa-
tients < 65 years or ≥ 65 years were 38% and 37%, respect-
ively [18]. In the Italian EAP, PFS and OS survival curves
were comparable between older and younger patients. Al-
though there was a tendency for survival to be better in the
elderly patient cohort, the differences in median PFS and
median OS between older and younger patients were not
statistically significant and were most likely to chance since
the inclusion and exclusion criteria were the same for all
patients, as was the follow-up duration, This finding is also
consistent with prespecified subgroup analyses of data from
the Phase III trial of ipilimumab in pretreated patients, in
which the survival benefit with ipilimumab monotherapy
compared with gp100 monotherapy was slightly but not
significantly greater in patients aged ≥65 years than in
younger patients (<65 years) [12,16]. Similarly, in the regis-
trational trial of vemurafenib, an inhibitor of mutated
BRAF, no differences in survival or response were reported
between older (≥ 65 years) and younger patients (< 65 years)
with metastatic melanoma [29].
Ipilimumab is associated with irAEs, which may reflect
the proposed mechanism of action [11,30]. Most irAEsare mild or moderate and, provided they are recognised
early, can be resolved effectively with appropriate manage-
ment [31]. Among patients > 70 years treated in the Italian
EAP, ipilimumab was generally well tolerated with only 6%
of patients experiencing Grade III–IV treatment-related
AEs. In addition, most elderly patients received all four
doses or discontinued treatment for reasons other than
toxicity. The AE profile of ipilimumab in patients aged >
70 years was again consistent with that observed in the
overall EAP population, with a similar incidence of Grade
III–IV treatment-related AEs and no unexpected toxic-
ities. The results were also in line with subgroup analyses
of safety data from patients treated with ipilimumab in
clinical trials, EAPs or as standard of care [12,19,24]. In
the US EAP, 11% patients aged ≥ 65 years had a Grade III–
IV irAE compared with 7% patients aged < 65 years [19].
Similarly, only four elderly patients (13%) treated in the
Spanish EAP had a Grade III–V AE and no patients dis-
continued treatment due to toxicity [20]. Taken together,
these results suggest that increased age does not comprom-
ise the tolerability of ipilimumab treatment. However, this
requires further validation in very elderly patients, as recent
data suggest that patients aged ≥ 75 years treated with
vemurafenib are more likely to experience AEs than youn-
ger patients, including secondary skin lesions, decreased
appetite and cardiac disorders [32].
The results of this EAP are particularly relevant as
they show that ipilimumab provides a consistent survival
benefit in patients aged over or under 70 years, despite
the fact that the immune system often becomes less ac-
tive in elderly people. Indeed, immunosenescence is an
important risk factor for melanoma and is thought to
affect all components of the immune system [8,9]. With
regard to adaptive immunity, an age-related reduction in
the proportion of naïve T cells occurs due to impaired
T-cell development in the thymus. Functional defects in
T-cell activity are also observed, partly due to a loss in
costimulatory molecules, including CD28 [33]. However,
ipilimumab may be particularly appropriate for the treat-
ment of elderly patients because the expression of coin-
hibitory receptors such as CTLA-4 increases with age
[34]. There is therefore a strong rationale for using anti-
CTLA-4 therapy to treat elderly patients with metastatic
melanoma in order to enhance adaptive immunity against
this disease.
Most data regarding the use of ipilimumab in older pa-
tients are provided by EAP analyses. The EAPs are a
valuable source of information regarding the efficacy
and safety of ipilimumab outside of clinical trials, but
they are also subject to limitations due to their retro-
spective, nonrandomised nature and the specific data
collected. For example, the effect of patient comorbidi-
ties on the efficacy and safety of ipilimumab in elderly
patients treated in the Italian EAP could not be assessed,
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the programme. In addition, it was not possible to stratify
patients by activities of daily living (ADL) and instrumen-
tal ADL scales, which would have better characterised the
patient population. However, these preliminary results
suggest that ipilimumab is a safe and effective treatment
option for elderly patients with metastatic melanoma.
Continued follow-up in this patient population will pro-
vide long-term efficacy and safety results.
Conclusions
Results from this analysis of elderly patients with advanced
melanoma treated as part of an EAP in Italy suggest that
ipilimumab 3 mg/kg is a well-tolerated treatment option,
providing clinical benefit and extending survival in these
patients. In addition, the clinical activity and safety profiles
of ipilimumab in patients aged > 70 years were consistent
with those observed in the wider population of the EAP.
Although this analysis is subject to limitations, these re-
sults suggest that age should not be a deciding factor when
considering whether to use ipilimumab to treat patients
with advanced melanoma.
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